Probiotic Interventions in Gastrointestinal Disorders

Probiotic interventions harness live microorganisms to restore and maintain gut homeostasis, targeting disorders from inflammatory bowel disease to colorectal cancer. Central to this approach is the modulation of dysbiosis—an imbalance in the native microbial community—through species- or strain-specific actions that reinforce barrier integrity, produce bioactive metabolites and shape host immune responses. Recent advances have focused on next-generation probiotics, including strictly anaerobic commensals, and their tolerance to oxygen, enabling formulation and delivery. Mechanistic insights reveal that short-chain fatty acids such as butyrate and acetate strengthen epithelial tight junctions and exert anti-inflammatory effects, while select strains induce regulatory T-cell subsets to dampen mucosal inflammation. These interventions hold global significance, offering cost-effective, low-risk adjuncts or alternatives to conventional therapies in both acute and chronic gastrointestinal conditions.

Research from Nature Portfolio

Researchers have developed a symbiotic formulation combining an adapted oxygen-tolerant strain of a key butyrate-producing bacterium with a complementary sulphate-reducing partner to achieve stable growth, butyrate generation and mucosal colonisation in preclinical and early human studies. This work demonstrates a scalable approach to cultivate strictly anaerobic next-generation probiotics under ambient conditions without compromising their metabolic benefits. A foundational study on a highly prevalent gut commensal identified a strain with exceptional capacity to stimulate interleukin-10 in dendritic cells, thereby reducing inflammatory markers and ameliorating colitis in murine models. Characterisation of its immunomodulatory profile revealed mechanisms underpinning the maintenance of intestinal immune homeostasis, highlighting this commensal as a candidate for clinical translation in inflammatory bowel disease.

Probiotic Interventions in Gastrointestinal Disorders publication trend

The graph below shows the total number of articles in probiotic interventions in gastrointestinal disorders across all publications each year (not limited to Nature Index journals).

Technical terms

Probiotic: Live microorganism which, when administered in adequate amounts, confers health benefits on the host.

Dysbiosis: Disruption or imbalance of the native gut microbial community associated with disease.

Short-chain fatty acids (SCFAs): Metabolites such as acetate, propionate and butyrate produced by microbial fermentation of dietary fibres, with key roles in barrier function and immune modulation.

Tight junctions: Protein complexes between adjacent epithelial cells that regulate paracellular permeability.

Tr1 cells: A subset of regulatory T cells characterised by high IL-10 production, involved in controlling mucosal inflammation.

Next-generation probiotics: Novel commensal strains, often strictly anaerobic, selected for targeted therapeutic properties beyond traditional lactic acid bacteria.

References

1. Synergy and oxygen adaptation for development of next-generation probiotics. Nature (2023).
2. Faecalibacterium prausnitzii A2-165 has a high capacity to induce IL-10 in human and murine dendritic cells and modulates T cell responses. Scientific Reports (2016).
3. Intraspecific difference of Latilactobacillus sakei in inflammatory bowel diseases: Insights into potential mechanisms through comparative genomics and metabolomics analyses. iMeta (2023).
4. Probiotic Bifidobacterium breve Induces IL-10-Producing Tr1 Cells in the Colon. PLOS Pathogens (2012).
5. Strengthening of the intestinal epithelial tight junction by Bifidobacterium bifidum. Physiological Reports (2015).